机构:[1]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China[2]Guangzhou Laboratory, Guangzhou, China[3]Department of Pulmonary and Critical Care Medicine, The First People’s Hospital of Yunnan Province, Kunming, China内科片外科片呼吸与危重症医学科重症医学科云南省第一人民医院[4]State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
The devastating COVID-19 pandemic caused by SARS-CoV-2 and multiple variants or subvariants remains an ongoing global challenge. SARS-CoV-2-specific T cell responses play a critical role in early virus clearance, disease severity control, limiting the viral transmission and underpinning COVID-19 vaccine efficacy. Studies estimated broad and robust T cell responses in each individual recognized at least 30 to 40 SARS-CoV-2 antigen epitopes and associated with COVID-19 clinical outcome. Several key immunodominant viral proteome epitopes, including S protein- and non-S protein-derived epitopes, may primarily induce potent and long-lasting antiviral protective effects. In this review, we summarized the immune response features of immunodominant epitope-specific T cells targeting different SRAS-CoV-2 proteome structures after infection and vaccination, including abundance, magnitude, frequency, phenotypic features and response kinetics. Further, we analyzed the epitopes immunodominance hierarchy in combination with multiple epitope-specific T cell attributes and TCR repertoires characteristics, and discussed the significant implications of cross-reactive T cells toward HCoVs, SRAS-CoV-2 and variants of concern, especially Omicron. This review may be essential for mapping the landscape of T cell responses toward SARS-CoV-2 and optimizing the current vaccine strategy.
基金:
This work was supported by the National Key Research and
Development Program of China [2019YFC0810900], Ministry of Science and Technology of the People Republic of China
[2021YFC0864400], NSFC [81971485, 82271801], Guangdong
Basic and Applied Basic Research Foundation [2019B1515120068,
2020B1111330001, 2022B1111070002], Emergency Key Program of
Guangzhou Laboratory [No.EKPG21-30-1], China Postdoctoral
Science Foundation [2021M690792] and Zhongnanshan Medical
Foundation of Guangdong Province [ZNSA-2020013].
第一作者机构:[1]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China[2]Guangzhou Laboratory, Guangzhou, China[3]Department of Pulmonary and Critical Care Medicine, The First People’s Hospital of Yunnan Province, Kunming, China
共同第一作者:
通讯作者:
通讯机构:[1]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China[2]Guangzhou Laboratory, Guangzhou, China[4]State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
推荐引用方式(GB/T 7714):
Yang Gang,Wang Junxiang,Sun Ping,et al.SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity[J].FRONTIERS IN IMMUNOLOGY.2023,14:doi:10.3389/fimmu.2023.1146196.
APA:
Yang, Gang,Wang, Junxiang,Sun, Ping,Qin, Jian,Yang, Xiaoyun...&Wang, Zhongfang.(2023).SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity.FRONTIERS IN IMMUNOLOGY,14,
MLA:
Yang, Gang,et al."SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity".FRONTIERS IN IMMUNOLOGY 14.(2023)